Option Care Health, Inc.
OPCHNasdaq
$21.74
↓ -1.6%Jul 17 close · end-of-day
Price
1Y↓ -28.5%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$3.4B
Enterprise Value
$4.4B
P/E
17.0
P/S
0.6
P/B
2.5
EV/EBITDA
11.1
PEG
1.1
FCF Yield
6.2%
Dividend Yield
—
Revenue (TTM)
$5.7B
Net Income (TTM)
$206.2M
Free Cash Flow (TTM)
$212.6M
Gross Margin
19.2%
Operating Margin
5.9%
Net Margin
3.6%
ROE
15.3%
ROIC
10.4%
Debt / Equity
0.9
Net Cash
-$982.5M
Return 1Y
-27.4%
Company profile
Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures. It also offers treatments to manage the progression of neurological disorders, such as amyotrophic lateral sclerosis and duchenne muscular dystrophy.
- CEO
- John C. Rademacher
- Sector
- Services
- Industry
- Healthcare
- Employees
- 5,600
- Headquarters
- Illinois
- Website
- optioncarehealth.com
Management & directors
- Bhatia PrateekEVP Sp Sales & Solutions
- Smyser CollinGC & Corporate Secretary
- Rademacher John CharlesChief Executive Officer
- Sethna MeenalChief Financial Officer
- Adewunmi FemiChief Medical Officer
- Bavaro MichaelChief Human Resources Officer
- Grashoff Christopher L.Chief Growth Officer
- Maggio NicoleChief Accounting Officer
- Whitworth LukeChief Operating Officer
Roles derived from SEC Form 4 filings.
Earnings
OPCH Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$1.4B↑ +1.3%
Diluted EPS$0.29↑ +3.6%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $3.0B | $3.4B | $3.9B | $4.3B | $5.0B | $5.6B |
| Gross profit | $682.3M | $779.6M | $866.9M | $981.2M | $1.0B | $1.1B |
| Operating income | $110.8M | $190.8M | $240.2M | $314.6M | $321.8M | $337.9M |
| Net income | -$8.1M | $139.9M | $150.6M | $267.1M | $211.8M | $207.6M |
| Diluted EPS | -$0.04 | $0.77 | $0.83 | $1.48 | $1.23 | $1.27 |
| Operating cash flow | $127.4M | $208.6M | $267.5M | $371.3M | $323.4M | $258.4M |
| Free cash flow | $100.5M | $182.9M | $232.2M | $329.4M | $287.8M | $217.1M |
| Gross margin | 22.5% | 22.7% | 22.0% | 22.8% | 20.3% | 19.3% |
| Operating margin | 3.7% | 5.5% | 6.1% | 7.3% | 6.4% | 6.0% |
| Net margin | -0.3% | 4.1% | 3.8% | 6.2% | 4.2% | 3.7% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2B | $1.3B | $1.3B | $1.3B | $1.4B | $1.4B | $1.5B | $1.4B |
| Gross profit | $249.4M | $256.7M | $268.4M | $263.1M | $269.0M | $272.9M | $282.9M | $262.0M |
| Operating income | $80.7M | $85.1M | $87.0M | $79.2M | $82.7M | $84.5M | $91.5M | $72.5M |
| Net income | $53.0M | $53.9M | $60.1M | $46.7M | $50.5M | $51.8M | $58.5M | $45.3M |
| Diluted EPS | $0.30 | $0.31 | $0.36 | $0.28 | $0.31 | $0.32 | $0.36 | $0.29 |
| Operating cash flow | $195.7M | $160.4M | $36.1M | -$7.2M | $90.3M | $139.4M | $35.9M | -$12.1M |
| Free cash flow | $185.9M | $150.7M | $25.8M | -$16.6M | $81.2M | $130.2M | $22.2M | -$21.2M |
| Gross margin | 20.3% | 20.1% | 19.9% | 19.7% | 19.0% | 19.0% | 19.3% | 19.4% |
| Operating margin | 6.6% | 6.7% | 6.5% | 5.9% | 5.8% | 5.9% | 6.2% | 5.4% |
| Net margin | 4.3% | 4.2% | 4.5% | 3.5% | 3.6% | 3.6% | 4.0% | 3.4% |
Company news
Jul 17, 2026
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
BoughtSoldMonthly insider $ volume · trailing 12 months
| Date | Insider | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|
| 2026-07-06 | Bhatia Prateek· EVP Sp Sales & Solutions | Award | 23,409 | $0.00 | $0.00 | filing |
| 2026-07-06 | Bhatia Prateek· EVP Sp Sales & Solutions | Award | 16,386 | $0.00 | $0.00 | filing |
| 2026-05-20 | KRAEMER HARRY M JANSEN JR | Award | 12,079 | $22.23 | $268,516.17 | filing |
| 2026-05-20 | SULLIVAN TIMOTHY P | Award | 4,836 | $22.23 | $107,504.28 | filing |
| 2026-05-20 | BRANDT ERIC | Award | 2,643 | $22.23 | $58,753.89 | filing |
| 2026-05-20 | Deckmann Natasha | Award | 844 | $22.23 | $18,762.12 | filing |
| 2026-05-20 | Pate R Carter | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | SULLIVAN TIMOTHY P | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | Deckmann Natasha | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | Bodem Barbara W. | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | Wright Norman L. | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | BRANDT ERIC | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | KRAEMER HARRY M JANSEN JR | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-20 | Bierbower Elizabeth D | Award | 8,997 | $0.00 | $0.00 | filing |
| 2026-05-19 | Smyser Collin· GC & Corporate Secretary | Tax withholding | 360 | $20.86 | $7,509.60 | filing |
| 2026-05-19 | Smyser Collin· GC & Corporate Secretary | Option exercise | 812 | $0.00 | $0.00 | filing |
| 2026-05-07 | SULLIVAN TIMOTHY P | Buy | 24,154 | $20.69 | $499,671.38 | filing |
| 2026-05-04 | KRAEMER HARRY M JANSEN JR | Buy | 36,610 | $21.41 | $783,772.51 | filing |
| 2026-05-04 | Sethna Meenal· Chief Financial Officer | Buy | 16,225 | $20.16 | $327,074.91 | filing |
| 2026-05-04 | RADEMACHER JOHN CHARLES· Chief Executive Officer | Buy | 12,500 | $21.18 | $264,706.25 | filing |
| 2026-04-22 | Adewunmi Femi· Chief Medical Officer | Tax withholding | 1,396 | $28.38 | $39,618.48 | filing |
| 2026-02-27 | Pate R Carter | Sale | 30,287 | $32.05 | $970,619.60 | filing |
| 2026-02-27 | Bavaro Michael· Chief Human Resources Officer | Sale | 6,000 | $33.00 | $198,000.00 | filing |
| 2026-02-24 | RADEMACHER JOHN CHARLES· Chief Executive Officer | Tax withholding | 11,050 | $33.82 | $373,655.75 | filing |
| 2026-02-24 | Whitworth Luke· Chief Operating Officer | Tax withholding | 4,605 | $33.82 | $155,718.08 | filing |
Showing the latest 25 transactions — full history in the linked SEC filings.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.